摘要
目的 探讨血管紧张素Ⅱ受体拮抗剂缬沙坦对高血压病患者血浆降钙素基因相关肽(CGRP)水平的影响。方法 29 例门诊高血压病患者接受缬沙坦治疗6周(80mg/d),以28例年龄匹配的正常血压者为对照,测定高血压病患者治疗前后及对照者的 血浆CGRP水平。结果 高血压病患者的血浆CGRP水平较对照者明显降低(最小值:0.00比39.95pg/ml;最大值:24.07比 155.59pg/ml;P<0.01);高血压病患者经缬沙坦治疗2～4周后,收缩压和舒张压明显降低(P<0.05);6周时维持血压稳定,血浆 CGRP水平则较治疗前显著升高(最小值:4.24比0.00pg/ml;最大值:101.53比24.07pg/ml;P<0.01)。缬沙坦治疗前后血浆CGRP 水平的增加值与收缩压降低值呈显著正相关(r=0.657,P<0.01)。结论 血管紧张素Ⅱ受体拮抗剂缬沙坦在降低血压的同时可明 显升高高血压病患者的血浆CGRP水平。
Objective To explore the effect of valasartan, an angiotensin Ⅱ type 1 (AT 1) receptor antagonist, on the plasma levels of calcitonin gene-related peptide (CGRP) in patients with essential hypertension. Methods 29 outpatients with essential hypertension were treated with valasartan 80mg/day for 6 weeks. 28 age-matched normal blood pressure people were taken as controls. The plasma levels of CGRP were measured in all patients before and after treatment and in controls. Results The plasma levels of CGRP in hypertensive patients were significantly lower than those in controls (minimal value: 0.00 vs 39.95pg/ml; maximal value: 24.07 vs 155.59pg/ml; P<0.01). In hypertensive patients, treatment with valasartan for 2~4 weeks markedly decreased systolic pressure and diastolic pressure and its depressor effect was maintained during the study (P<0.05). At 6 week after treatment, the plasma levels of CGRP in hypertensive patients were significantly increased compared with those before treatment (minimal value: 4.24 vs 0.00pg/ml; maximal value: 101.53 vs 24.07pg/ml; P<0.01). The increase of plasma CGRP was positively correlated with the decrease of systolic blood pressure during valasartan treatment (r=0.657, P<0.01). Conclusion Valasartan significantly decreases blood pressure concomitantly with an increase in the plasma levels of CGRP in the patients with essential hypertension.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2005年第3期260-262,共3页
Medical Journal of Chinese People's Liberation Army
关键词
高血压
降钙素基因相关肽
缬沙坦
hypertension
calcitonin gene-related peptide
valasartan
